228 related articles for article (PubMed ID: 35511393)
1. Evolving Treatment Approaches to Mucosal Melanoma.
Zhang S; Zhang J; Guo J; Si L; Bai X
Curr Oncol Rep; 2022 Oct; 24(10):1261-1271. PubMed ID: 35511393
[TBL] [Abstract][Full Text] [Related]
2. Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis.
Wrede N; Hoffmann I; Vollbrecht C; Koch I; Wolkenstein P; Klauschen F; Capper D; von Laffert M; Jurmeister P
Pathol Res Pract; 2022 Jan; 229():153689. PubMed ID: 34844086
[TBL] [Abstract][Full Text] [Related]
3. JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy.
Gupta S; Vanderbilt CM; Cotzia P; Arias Stella JA; Chang JC; Chen Y; Tang LH; DeLair DF; Yao J; Ladanyi M; Ross DS
Hum Pathol; 2019 Jun; 88():87-91. PubMed ID: 30236595
[TBL] [Abstract][Full Text] [Related]
4. Management of Acral and Mucosal Melanoma: Medical Oncology Perspective.
Jung S; Johnson DB
Oncologist; 2022 Aug; 27(8):703-710. PubMed ID: 35640549
[TBL] [Abstract][Full Text] [Related]
5. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.
Tang B; Yan X; Sheng X; Si L; Cui C; Kong Y; Mao L; Lian B; Bai X; Wang X; Li S; Zhou L; Yu J; Dai J; Wang K; Hu J; Dong L; Song H; Wu H; Feng H; Yao S; Chi Z; Guo J
J Hematol Oncol; 2019 Jan; 12(1):7. PubMed ID: 30642373
[TBL] [Abstract][Full Text] [Related]
6. The mutational landscape of mucosal melanoma.
Nassar KW; Tan AC
Semin Cancer Biol; 2020 Apr; 61():139-148. PubMed ID: 31655118
[TBL] [Abstract][Full Text] [Related]
7. Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review.
Indini A; Roila F; Grossi F; Massi D; Mandalà M
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008570
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
[TBL] [Abstract][Full Text] [Related]
9. Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives.
Marra A; Ferrone CR; Fusciello C; Scognamiglio G; Ferrone S; Pepe S; Perri F; Sabbatino F
Anticancer Agents Med Chem; 2018; 18(2):166-181. PubMed ID: 29256359
[TBL] [Abstract][Full Text] [Related]
10. Treatment of acral and mucosal melanoma: Current and emerging targeted therapies.
Zhang J; Tian H; Mao L; Si L
Crit Rev Oncol Hematol; 2024 Jan; 193():104221. PubMed ID: 38036156
[TBL] [Abstract][Full Text] [Related]
11. Mucosal melanoma: from molecular landscape to current treatment strategies.
Mattei J; Trindade EN; Chedid MF
Melanoma Res; 2023 Dec; 33(6):447-453. PubMed ID: 37650711
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
Frydenlund N; Mahalingam M
Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.
Mao L; Qi Z; Zhang L; Guo J; Si L
Front Immunol; 2021; 12():680407. PubMed ID: 34149718
[TBL] [Abstract][Full Text] [Related]
14. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
Komatsubara KM; Carvajal RD
Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.
Shi VJ; Rodic N; Gettinger S; Leventhal JS; Neckman JP; Girardi M; Bosenberg M; Choi JN
JAMA Dermatol; 2016 Oct; 152(10):1128-1136. PubMed ID: 27411054
[TBL] [Abstract][Full Text] [Related]
17. [Immunotherapies and melanoma].
Routier É; Robert C; Mateus C
Bull Cancer; 2014 Dec; 101 Suppl 2():S13-24. PubMed ID: 25776763
[TBL] [Abstract][Full Text] [Related]
18. Targeting the PD-1 pathway: a promising future for the treatment of melanoma.
Mamalis A; Garcha M; Jagdeo J
Arch Dermatol Res; 2014 Aug; 306(6):511-9. PubMed ID: 24615548
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.
Sullivan RJ; Hamid O; Gonzalez R; Infante JR; Patel MR; Hodi FS; Lewis KD; Tawbi HA; Hernandez G; Wongchenko MJ; Chang Y; Roberts L; Ballinger M; Yan Y; Cha E; Hwu P
Nat Med; 2019 Jun; 25(6):929-935. PubMed ID: 31171876
[TBL] [Abstract][Full Text] [Related]
20. Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy.
Maniyar RR; Chakraborty S; Jarboe T; Suriano R; Wallack M; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():123-143. PubMed ID: 34888847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
